Japan introduced a new health coverage scheme for long-listed products (LLPs) on October 1. A survey of generic drug makers…
HOME > REGULATORY
REGULATORY
- Wholesalers Call on Drug Makers to “Flexibly” Revise Invoice Prices
February 3, 2014
- PAFSC Committee Designates OTC PMS Treatment as First “Drug Requiring Guidance”
January 31, 2014
- Medical Fee Cuts Will Start from FY2014 to Improve Delivery Price Settlement Rates: Chuikyo
January 30, 2014
- Wary of Drug Price Negotiations Dragging Out into FY2014, MHLW to Survey Price Agreement Rate in March
January 30, 2014
- 2 Bills Related to the Establishment of a “Japanese NIH” to Be Submitted to the Diet in Early February
January 30, 2014
- 3 Entities Strike Codevelopment Deal for Adult TB Vaccines
January 29, 2014
- Rivaroxaban Under Review for Risk of Interstitial Pneumonia: PMDA
January 29, 2014
- PAFSC’s Second Committee to Review Taiho’s Novel Anticancer Agent on Feb. 3
January 28, 2014
- MHLW Setting Out on Development of iPS Tech-Based Cardiotoxicity Evaluation
January 28, 2014
- PAFSC’s First Committee Supports Approval of Second SGLT-2 Inhibitor Dapagliflozin
January 27, 2014
- FDA Bans Imports from Ranbaxy’s Toansa Plant, Daiichi Sankyo Promises Full Cooperation with FDA
January 27, 2014
- Health Minister Waits for Investigation Results on Novartis Involvement in “Sign” Study
January 27, 2014
- Comprehensive Strategy Proposal for “Japan NIH” Calls for Study on Legislation to Prevent Clinical Research Fraud by Autumn
January 27, 2014
- Expert Groups Call for Early Resumption of Active Recommendation for HPV Vaccines
January 27, 2014
- Regulatory Reform Council Eyes New Special System for Mixed Healthcare
January 24, 2014
- NHI Pricing of Generics Set to Undergo Major Revision to Help MHLW Achieve New Target; Promotion through Medical Fee Revision Also Planned
January 24, 2014
- DPP-4 Inhibitors, Remicade to Face Market Expansion Re-Pricing in FY2014 Revision
January 23, 2014
- Chuikyo OKs New NHI Drug Pricing Rules for FY2014 Revision
January 23, 2014
- Gov’t to Fully Implement Japan Version of “Compassionate Use” System in FY2015
January 23, 2014
- Final Decision on Active Recommendation for HPV Vaccines Will Be Made at Next Subcommittee Meeting: Minister
January 23, 2014
ページ
It’s easy to spot motivated and engaged employees. They are more productive, they go the extra mile, and they display a sense of ownership in their work.But how do you replicate this culture throughout your organization? How do you encourage…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
The Japanese health ministry on December 22 approved a batch of medicines for additional indications, including Otsuka Pharmaceutical’s atypical antipsychotic Rexulti (brexpiprazole) and Zenyaku Kogyo’s anti-CD20 antibody Rituxan (rituximab).Rexulti is now newly indicated for the treatment of depression and depressive…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
A key Japanese reimbursement policy panel on December 16 approved the government-backed plan for the FY2023 “off-year” drug price revision.…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…